通过抗氧化压力治疗肝脏疾病的西利宾:综合性审查
Chao Cui1, Jingfei Shi2, Yu Sun1
1Department of Infectious Disease, Qilu Hospital of Shandong University, Dezhou Hospital, Dezhou, China.
The American journal of Chinese medicine
|January 6, 2026
概括
来自乳的西利宾,通过其抗氧化和抗炎作用,显示出治疗肝脏疾病的前景. 需要进一步的研究来确认其有效性和安全性,以便广泛的临床使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 自然产品 化学 化学
背景情况:
- 肝病是全球主要的健康问题,需要有效的预防和治疗.
- 西利宾是乳 (Silybum marianum) 的一个主要活性成分,具有显著的抗氧化特性.
- 这些特性使西利宾成为各种肝病的潜在治疗剂,包括肝炎,肝硬化和肝癌.
研究的目的:
- 审查关于西利宾在肝脏疾病中的治疗作用的研究,重点关注其抗氧化应激机制.
- 突出新型西利宾药物配方的开发,针对参与肝病病原发生的特定途径.
- 检查目前用于治疗肝病的西利宾配方的全球应用.
主要方法:
- 关于近几十年来西利宾和肝脏疾病研究的综合文献综述.
- 在肝病进展中分析西利宾的双重抗氧化和抗炎机制.
- 研究针对特定受体和蛋白质 (例如CD44,CXCR4,GLUT4,SPARC) 的新型药物配方.
主要成果:
- 西利宾在急性肝炎,慢性肝炎和肝硬化中显示出显著的治疗潜力.
- 它的机制包括缓解炎症和促进肝病状态的有益转变.
- 针对特定分子通路的新型配方显示出改善治疗结果的希望.
结论:
- 西利宾是治疗肝脏疾病的有希望的候选者,因为它具有强大的抗氧化和抗炎作用.
- 针对性药物配方是推进基于西利宾的疗法的一个关键领域.
- 进一步进行高质量的临床研究至关重要,以确定西利宾在广泛肝病治疗中的有效性和安全性.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
01:26Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
208
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
208